142 related articles for article (PubMed ID: 23147994)
21. hMSH2 coordinated with the expression of E2F1 promotes platinum response in epithelial ovarian cancer.
Hu XQ; Zhang BY; Hua T
J Int Med Res; 2023 Mar; 51(3):3000605231163780. PubMed ID: 36994850
[TBL] [Abstract][Full Text] [Related]
22. Puerarin induces platinum-resistant epithelial ovarian cancer cell apoptosis by targeting SIRT1.
Duan J; Yin M; Shao Y; Zheng J; Nie S
J Int Med Res; 2021 Sep; 49(9):3000605211040762. PubMed ID: 34590923
[TBL] [Abstract][Full Text] [Related]
23. Metabolic modulation of CtBP dimeric status impacts the repression of DNA damage repair genes and the platinum sensitivity of ovarian cancer.
Li J; Wang Y; Wang L; Hao D; Li P; Su M; Zhao Z; Liu T; Tai L; Lu J; Di LJ
Int J Biol Sci; 2023; 19(7):2081-2096. PubMed ID: 37151877
[TBL] [Abstract][Full Text] [Related]
24. FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy.
Diaz Osterman CJ; Ozmadenci D; Kleinschmidt EG; Taylor KN; Barrie AM; Jiang S; Bean LM; Sulzmaier FJ; Jean C; Tancioni I; Anderson K; Uryu S; Cordasco EA; Li J; Chen XL; Fu G; Ojalill M; Rappu P; Heino J; Mark AM; Xu G; Fisch KM; Kolev VN; Weaver DT; Pachter JA; Győrffy B; McHale MT; Connolly DC; Molinolo A; Stupack DG; Schlaepfer DD
Elife; 2019 Sep; 8():. PubMed ID: 31478830
[TBL] [Abstract][Full Text] [Related]
25. Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer.
Sriramkumar S; Sood R; Huntington TD; Ghobashi AH; Vuong TT; Metcalfe TX; Wang W; Nephew KP; O'Hagan HM
J Transl Med; 2022 May; 20(1):246. PubMed ID: 35641987
[TBL] [Abstract][Full Text] [Related]
26. The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer.
Hopkins TG; Mura M; Al-Ashtal HA; Lahr RM; Abd-Latip N; Sweeney K; Lu H; Weir J; El-Bahrawy M; Steel JH; Ghaem-Maghami S; Aboagye EO; Berman AJ; Blagden SP
Nucleic Acids Res; 2016 Feb; 44(3):1227-46. PubMed ID: 26717985
[TBL] [Abstract][Full Text] [Related]
27. Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targets.
da Costa AABA; Baiocchi G
Semin Cancer Biol; 2021 Dec; 77():29-41. PubMed ID: 33161141
[TBL] [Abstract][Full Text] [Related]
28. Hormone response in ovarian cancer: time to reconsider as a clinical target?
Modugno F; Laskey R; Smith AL; Andersen CL; Haluska P; Oesterreich S
Endocr Relat Cancer; 2012 Dec; 19(6):R255-79. PubMed ID: 23045324
[TBL] [Abstract][Full Text] [Related]
29. Secreted Soluble Factors from Tumor-Activated Mesenchymal Stromal Cells Confer Platinum Chemoresistance to Ovarian Cancer Cells.
Koren Carmi Y; Khamaisi H; Adawi R; Noyman E; Gopas J; Mahajna J
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175439
[TBL] [Abstract][Full Text] [Related]
30. mTORC1/2 inhibition re-sensitizes platinum-resistant ovarian cancer by disrupting selective translation of DNA damage and survival mRNAs.
David-West G; Ernlund A; Gadi A; Schneider RJ
Oncotarget; 2018 Sep; 9(69):33064-33076. PubMed ID: 30237852
[TBL] [Abstract][Full Text] [Related]
31. Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancers.
Alblihy A; Ali R; Algethami M; Shoqafi A; Toss MS; Brownlie J; Tatum NJ; Hickson I; Moran PO; Grabowska A; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
NPJ Precis Oncol; 2022 Jul; 6(1):51. PubMed ID: 35853939
[TBL] [Abstract][Full Text] [Related]
32. Effective sequential combined therapy with carboplatin and a CDC7 inhibitor in ovarian cancer.
Li J; Hu H; He J; Hu Y; Liu M; Cao B; Chen D; Ye X; Zhang J; Zhang Z; Long W; Lian H; Chen D; Chen L; Yang L; Zhang Z
Transl Oncol; 2024 Jan; 39():101825. PubMed ID: 37992591
[TBL] [Abstract][Full Text] [Related]
33. The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer.
Patel M; Wang Y; Bartom ET; Dhir R; Nephew KP; Matei D; Murmann AE; Lengyel E; Peter ME
Cancer Res; 2021 Aug; 81(15):3985-4000. PubMed ID: 34224372
[TBL] [Abstract][Full Text] [Related]
34. A highly annotated database of genes associated with platinum resistance in cancer.
Huang D; Savage SR; Calinawan AP; Lin C; Zhang B; Wang P; Starr TK; Birrer MJ; Paulovich AG
Oncogene; 2021 Nov; 40(46):6395-6405. PubMed ID: 34645978
[TBL] [Abstract][Full Text] [Related]
35. Multimerin 1 aids in the progression of ovarian cancer possibly via modulation of DNA damage response and repair pathways.
Saini A; Kumar V; Tomar AK; Sharma A; Yadav S
Mol Cell Biochem; 2023 Oct; 478(10):2395-2403. PubMed ID: 36723821
[TBL] [Abstract][Full Text] [Related]
36. Insight into autophagy in platinum resistance of cancer.
Yang F; Xu K; Zhou YG; Ren T
Int J Clin Oncol; 2023 Mar; 28(3):354-362. PubMed ID: 36705869
[TBL] [Abstract][Full Text] [Related]
37. DNA base excision repair gene variants and susceptibility to ovarian cancer.
Yasri S; Wiwanitkit V
J Cancer Res Ther; 2022; 18(1):321. PubMed ID: 35381814
[No Abstract] [Full Text] [Related]
38. Metabolic reprogramming of three major nutrients in platinum-resistant ovarian cancer.
Yan J; Xu F; Zhou D; Zhang S; Zhang B; Meng Q; Lv Q
Front Oncol; 2023; 13():1231460. PubMed ID: 37681030
[TBL] [Abstract][Full Text] [Related]
39. Cancer stem cells markers in ovarian cancer: Clinical and therapeutic significance (Review).
Królewska-Daszczyńska P; Wendlocha D; Smycz-Kubańska M; Stępień S; Mielczarek-Palacz A
Oncol Lett; 2022 Dec; 24(6):465. PubMed ID: 36406181
[TBL] [Abstract][Full Text] [Related]
40. Endothelial
Li H; Cheng Z; Yang P; Huang W; Li X; Xiang D; Wu X
Cells; 2022 Sep; 11(19):. PubMed ID: 36231046
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
